MovDisordV3, Main, Exploration, bibRecord, 002441

Atypical antipsychotic use and risk of fracture in persons with Parkinsonism

Identifieur interne : 002441 ( Main/Exploration ); précédent : 002440; suivant : 002442

Atypical antipsychotic use and risk of fracture in persons with Parkinsonism

Auteurs : David D. Dore [États-Unis] ; Amal N. Trivedi [États-Unis] ; Vincent Mor [États-Unis] ; Joseph H. Friedman [États-Unis] ; Kate L. Lapane [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2009-10-15.

RBID : ISTEX:AE6BD0184166F85F9711793ED25FB1DB7E52AED6

Descripteurs français

Pascal (Inist)
- Antipsychotique, Facteur risque, Fracture, Parkinsonisme, Pathologie du système nerveux.
Wicri :
- geographic : États-Unis.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Antipsychotic, Antipsychotic Agents (adverse effects), Antipsychotic Agents (classification), Antipsychotic Agents (therapeutic use), Case-Control Studies, Confidence Intervals, Databases, Factual (statistics & numerical data), Female, Fracture, Fractures, Bone (chemically induced), Humans, Logistic Models, Male, Medicaid (statistics & numerical data), Middle Aged, Nervous system diseases, Odds Ratio, Parkinsonian Disorders (drug therapy), Parkinsonism, Risk Assessment, Risk Factors, Risk factor, United States, atypical antipsychotic, fracture, parkinsonism, pharmacoepidemiology.
MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , classification : Antipsychotic Agents.
- chemical , therapeutic use : Antipsychotic Agents.
- geographic : United States.
- chemically induced : Fractures, Bone.
- drug therapy : Parkinsonian Disorders.
- statistics & numerical data : Databases, Factual, Medicaid.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Confidence Intervals, Female, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Risk Assessment, Risk Factors.

Abstract

Our objective was to estimate the effect of atypical antipsychotics (AAs) on the rate of fractures in a parkinsonism population. We conducted an age‐ and state‐matched nested case‐control study in five states (CA, FL, NY, OH, IL) using the Medicaid analytic extract from 2001 to 2002. Eligible participants had a diagnosis of parkinsonism, excluding persons with secondary parkinsonism, bone cancer, bone infections, schizophrenia, schizoaffective disorder, and those who used conventional antipsychotics. The primary outcome was the occurrence of a fracture of the femur, ankle, fibula, tibia, humerus, radius, or ulna (N = 851). Risk‐set sampling defined controls (N = 4220). We used conditional‐logistic regression to derive adjusted odds ratios (AOR) and 95% confidence intervals of the association between fracture and use of quetiapine, risperidone, or olanzapine in the 60 days before the index date compared to nonuse. After adjustment for confounding, use of quetiapine (AOR 2.4; 95% CI 1.5–3.8), risperidone (AOR 1.2; 95% CI 0.9–1.7), or olanzapine (AOR 1.7; 95% CI 1.2–2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism. © 2009 Movement Disorder Society

Url:

https://api.istex.fr/document/AE6BD0184166F85F9711793ED25FB1DB7E52AED6/fulltext/pdf

DOI: 10.1002/mds.22679

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atypical antipsychotic use and risk of fracture in persons with Parkinsonism</title>
<author><name sortKey="Dore, David D" sort="Dore, David D" uniqKey="Dore D" first="David D." last="Dore">David D. Dore</name>
</author>
<author><name sortKey="Trivedi, Amal N" sort="Trivedi, Amal N" uniqKey="Trivedi A" first="Amal N." last="Trivedi">Amal N. Trivedi</name>
</author>
<author><name sortKey="Mor, Vincent" sort="Mor, Vincent" uniqKey="Mor V" first="Vincent" last="Mor">Vincent Mor</name>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
</author>
<author><name sortKey="Lapane, Kate L" sort="Lapane, Kate L" uniqKey="Lapane K" first="Kate L." last="Lapane">Kate L. Lapane</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AE6BD0184166F85F9711793ED25FB1DB7E52AED6</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22679</idno>
<idno type="url">https://api.istex.fr/document/AE6BD0184166F85F9711793ED25FB1DB7E52AED6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000853</idno>
<idno type="wicri:Area/Istex/Curation">000853</idno>
<idno type="wicri:Area/Istex/Checkpoint">001043</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Dore D:atypical:antipsychotic:use</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19645066</idno>
<idno type="wicri:Area/PubMed/Corpus">001C12</idno>
<idno type="wicri:Area/PubMed/Curation">001C12</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001F44</idno>
<idno type="wicri:Area/Ncbi/Merge">002765</idno>
<idno type="wicri:Area/Ncbi/Curation">002765</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002765</idno>
<idno type="wicri:Area/Main/Merge">002D02</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0472201</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D54</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001F65</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F74</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Dore D:atypical:antipsychotic:use</idno>
<idno type="wicri:Area/Main/Merge">003071</idno>
<idno type="wicri:Area/Main/Curation">002441</idno>
<idno type="wicri:Area/Main/Exploration">002441</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Atypical antipsychotic use and risk of fracture in persons with Parkinsonism</title>
<author><name sortKey="Dore, David D" sort="Dore, David D" uniqKey="Dore D" first="David D." last="Dore">David D. Dore</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>i3 Drug Safety, Waltham, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Community Health, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trivedi, Amal N" sort="Trivedi, Amal N" uniqKey="Trivedi A" first="Amal N." last="Trivedi">Amal N. Trivedi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Community Health, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Gerontology and Health Care Research, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mor, Vincent" sort="Mor, Vincent" uniqKey="Mor V" first="Vincent" last="Mor">Vincent Mor</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Community Health, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Gerontology and Health Care Research, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>NeuroHealth, Warwick, Rhode Island and Department of Clinical Neurosciences, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lapane, Kate L" sort="Lapane, Kate L" uniqKey="Lapane K" first="Kate L." last="Lapane">Kate L. Lapane</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Community Health, The Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Epidemiology and Community Health, Virginia Commonwealth University, Richmond, Virginia</wicri:regionArea>
<placeName><region type="state">Virginie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-10-15">2009-10-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="1941">1941</biblScope>
<biblScope unit="page" to="1948">1948</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">AE6BD0184166F85F9711793ED25FB1DB7E52AED6</idno>
<idno type="DOI">10.1002/mds.22679</idno>
<idno type="ArticleID">MDS22679</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antipsychotic</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (classification)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Case-Control Studies</term>
<term>Confidence Intervals</term>
<term>Databases, Factual (statistics & numerical data)</term>
<term>Female</term>
<term>Fracture</term>
<term>Fractures, Bone (chemically induced)</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Medicaid (statistics & numerical data)</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Odds Ratio</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonism</term>
<term>Risk Assessment</term>
<term>Risk Factors</term>
<term>Risk factor</term>
<term>United States</term>
<term>atypical antipsychotic</term>
<term>fracture</term>
<term>parkinsonism</term>
<term>pharmacoepidemiology</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fractures, Bone</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Databases, Factual</term>
<term>Medicaid</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>Confidence Intervals</term>
<term>Female</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Odds Ratio</term>
<term>Risk Assessment</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term>
<term>Facteur risque</term>
<term>Fracture</term>
<term>Parkinsonisme</term>
<term>Pathologie du   système nerveux</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Our objective was to estimate the effect of atypical antipsychotics (AAs) on the rate of fractures in a parkinsonism population. We conducted an age‐ and state‐matched nested case‐control study in five states (CA, FL, NY, OH, IL) using the Medicaid analytic extract from 2001 to 2002. Eligible participants had a diagnosis of parkinsonism, excluding persons with secondary parkinsonism, bone cancer, bone infections, schizophrenia, schizoaffective disorder, and those who used conventional antipsychotics. The primary outcome was the occurrence of a fracture of the femur, ankle, fibula, tibia, humerus, radius, or ulna (N = 851). Risk‐set sampling defined controls (N = 4220). We used conditional‐logistic regression to derive adjusted odds ratios (AOR) and 95% confidence intervals of the association between fracture and use of quetiapine, risperidone, or olanzapine in the 60 days before the index date compared to nonuse. After adjustment for confounding, use of quetiapine (AOR 2.4; 95% CI 1.5–3.8), risperidone (AOR 1.2; 95% CI 0.9–1.7), or olanzapine (AOR 1.7; 95% CI 1.2–2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
<li>Rhode Island</li>
<li>Virginie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Dore, David D" sort="Dore, David D" uniqKey="Dore D" first="David D." last="Dore">David D. Dore</name>
</region>
<name sortKey="Dore, David D" sort="Dore, David D" uniqKey="Dore D" first="David D." last="Dore">David D. Dore</name>
<name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<name sortKey="Lapane, Kate L" sort="Lapane, Kate L" uniqKey="Lapane K" first="Kate L." last="Lapane">Kate L. Lapane</name>
<name sortKey="Lapane, Kate L" sort="Lapane, Kate L" uniqKey="Lapane K" first="Kate L." last="Lapane">Kate L. Lapane</name>
<name sortKey="Mor, Vincent" sort="Mor, Vincent" uniqKey="Mor V" first="Vincent" last="Mor">Vincent Mor</name>
<name sortKey="Mor, Vincent" sort="Mor, Vincent" uniqKey="Mor V" first="Vincent" last="Mor">Vincent Mor</name>
<name sortKey="Trivedi, Amal N" sort="Trivedi, Amal N" uniqKey="Trivedi A" first="Amal N." last="Trivedi">Amal N. Trivedi</name>
<name sortKey="Trivedi, Amal N" sort="Trivedi, Amal N" uniqKey="Trivedi A" first="Amal N." last="Trivedi">Amal N. Trivedi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002441 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002441 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:AE6BD0184166F85F9711793ED25FB1DB7E52AED6
   |texte=   Atypical antipsychotic use and risk of fracture in persons with Parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Atypical antipsychotic use and risk of fracture in persons with Parkinsonism

Atypical antipsychotic use and risk of fracture in persons with Parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.